BidaskClub Lowers Aduro BioTech (ADRO) to Strong Sell
BidaskClub lowered shares of Aduro BioTech (NASDAQ:ADRO) from a sell rating to a strong sell rating in a research report sent to investors on Wednesday.
A number of other equities analysts have also commented on ADRO. Oppenheimer initiated coverage on shares of Aduro BioTech in a research note on Monday, October 30th. They issued a buy rating and a $15.00 price objective for the company. HC Wainwright set a $18.00 price objective on shares of Aduro BioTech and gave the stock a buy rating in a research note on Wednesday, November 1st. Canaccord Genuity set a $30.00 price objective on shares of Aduro BioTech and gave the stock a buy rating in a research note on Thursday, December 14th. Finally, ValuEngine lowered shares of Aduro BioTech from a sell rating to a strong sell rating in a research note on Friday, February 2nd. Two analysts have rated the stock with a sell rating, one has issued a hold rating and nine have given a buy rating to the company’s stock. The company has a consensus rating of Buy and an average target price of $17.71.
Aduro BioTech (ADRO) opened at $6.10 on Wednesday. Aduro BioTech has a 52 week low of $5.82 and a 52 week high of $14.05.
A number of hedge funds have recently added to or reduced their stakes in the business. Harvard Management Co. Inc. purchased a new stake in Aduro BioTech in the 3rd quarter worth approximately $69,418,000. Vanguard Group Inc. raised its holdings in shares of Aduro BioTech by 5.4% during the 2nd quarter. Vanguard Group Inc. now owns 2,511,995 shares of the biotechnology company’s stock valued at $28,637,000 after purchasing an additional 129,079 shares in the last quarter. State Street Corp raised its holdings in shares of Aduro BioTech by 8.3% during the 2nd quarter. State Street Corp now owns 684,699 shares of the biotechnology company’s stock valued at $7,808,000 after purchasing an additional 52,597 shares in the last quarter. Baillie Gifford & Co. raised its holdings in shares of Aduro BioTech by 30.8% during the 3rd quarter. Baillie Gifford & Co. now owns 553,090 shares of the biotechnology company’s stock valued at $5,891,000 after purchasing an additional 130,390 shares in the last quarter. Finally, Northern Trust Corp raised its holdings in shares of Aduro BioTech by 15.1% during the 2nd quarter. Northern Trust Corp now owns 453,115 shares of the biotechnology company’s stock valued at $5,166,000 after purchasing an additional 59,490 shares in the last quarter. Institutional investors own 42.61% of the company’s stock.
WARNING: This piece was originally reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this piece on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece can be viewed at https://theolympiareport.com/2018/02/22/bidaskclub-lowers-aduro-biotech-adro-to-strong-sell.html.
Aduro BioTech Company Profile
Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.
Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.